Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis

26 Feb 2025

Abstract excerpt

Background/Aim: Ocrelizumab, a CD20-targeting monoclonal antibody, is used for treatment of multiple sclerosis. The aim of this study was to explore the utility of peripheral blood cell subsets in prediction of treatment response to ocrelizumab in relapsing remitting multiple sclerosis (RRMS). Patients and Methods: Thirty-one patients with RRMS resistant to first-line immunomodulating agents were enrolled and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Sclerosis Research Studies
Share to T-cell and B-cell Immunology
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40010950
DOI: 10.21873/invivo.13920

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple SclerosisPMID 40010950Read ↗

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity Read ↗

Effect of Cumulative Exposure to Ocrelizumab on Memory B‐Cell Repopulation Dynamics in Multiple SclerosisSemantic proximity Read ↗

Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity Read ↗

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with OcrelizumabSemantic proximity Read ↗

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activitySemantic proximity Read ↗

Low memory T cells blood counts and high naïve regulatory T cells percentage at relapsing remitting multiple sclerosis diagnosisSemantic proximity Read ↗

Role of CD8 T cell subsets in the pathogenesis of multiple sclerosisSemantic proximity Read ↗

CD4 and CD8 lymphocyte subsets in cerebrospinal fluid and peripheral blood from patients with multiple sclerosis, meningitis and normal controls.Semantic proximity Read ↗

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.Semantic proximity Read ↗

Association between peripheral blood immunological status and intrathecal inflammatory markers differentiate multiple sclerosis clinical phenotypes.Semantic proximity Read ↗

Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.Semantic proximity Read ↗

Deficiency of CD8 <sup>+</sup> effector memory T cells is an early and persistent feature of multiple sclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.